


Open Access

Hazem A. Ghabbour*, Bakr F. Abdel-Wahab, Mohammed Baashen, Majid Mohammad Asmari and Gamal A. El-Hiti

Crystal structure of 3-(4-bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide, $C_{16}H_{13}BrFN_3S$



The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1: Data collection and handling.

Crystal:	Colourless plates
Wavelength:	Size $0.68 \times 0.37 \times 0.12$ mm
μ :	Mo K_{α} radiation (0.71073 Å)
Diffractionmeter, scan mode:	28.9 cm ⁻¹
$2\theta_{\max}$, completeness:	Broker APEX-II, φ and ω
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	58.6°, >99%
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	21750, 4371, 0.103
$N(\text{param})_{\text{refined}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 3162
Programs:	207
	SHELX [6], Bruker programs [7]

DOI 10.1515/ncrs-2016-0057

Received February 15, 2016; accepted June 3, 2016; available online June 11, 2016

Abstract

$C_{16}H_{13}BrFN_3S$, monoclinic, $P2_1/c$, $a = 14.6734(6)$ Å, $b = 11.1226(5)$ Å, $c = 9.4184(4)$ Å, $\beta = 102.524(2)^\circ$, $V = 1500.57(11)$ Å³, $Z = 4$, $R_{\text{gt}}(F) = 0.0473$, $wR_{\text{ref}}(F^2) = 0.1182$, $T = 100$ K.

CCDC no.: 1452283

***Corresponding author: Hazem A. Ghabbour**, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia, e-mail: ghabbour@yahoo.com; and Faculty of Pharmacy, Department of Medicinal Chemistry, University of Mansoura, Mansoura 35516, Egypt

Bakr F. Abdel-Wahab: Department of Chemistry, College of Science and Humanities, Shaqra University, Duwadimi, Saudi Arabia; and Applied Organic Chemistry Department, National Research Centre, Dokki, Giza, Egypt

Mohammed Baashen: Department of Chemistry, College of Science and Humanities, Shaqra University, Duwadimi, Saudi Arabia

Majid Mohammad Asmari: Research Centre, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

Gamal A. El-Hiti: Cornea Research Chair, Department of Optometry, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	<i>x</i>	<i>y</i>	<i>z</i>	$U_{\text{iso}}^*/U_{\text{eq}}$
Br1	0.44696(2)	0.15662(3)	0.00851(3)	0.01972(11)
S1	1.01214(5)	0.66563(6)	0.65912(8)	0.01185(15)
F1	0.73592(13)	0.64557(14)	1.11962(18)	0.0181(4)
N1	0.79310(15)	0.5003(2)	0.4233(2)	0.0105(5)
N2	0.86648(15)	0.53044(19)	0.5376(2)	0.0092(4)
N3	0.90095(19)	0.6816(2)	0.3963(3)	0.0128(5)
C1	0.6293(2)	0.4069(3)	0.2376(3)	0.0148(6)
H1A	0.6406	0.4905	0.2306	0.018*
C2	0.5583(2)	0.3529(2)	0.1380(3)	0.0159(6)
H2A	0.5209	0.3989	0.0622	0.019*
C3	0.54196(19)	0.2305(2)	0.1495(3)	0.0131(6)
C4	0.5945(2)	0.1621(2)	0.2604(3)	0.0146(6)
H4A	0.5820	0.0788	0.2679	0.017*
C5	0.66584(18)	0.2170(2)	0.3605(3)	0.0128(6)
H5A	0.7020	0.1710	0.4376	0.015*
C6	0.68495(19)	0.3393(2)	0.3491(3)	0.0109(5)
C7	0.76343(18)	0.3951(2)	0.4513(3)	0.0102(5)
C8	0.81851(19)	0.3397(2)	0.5885(3)	0.0105(5)
H8A	0.8586	0.2735	0.5671	0.013*
H8B	0.7770	0.3087	0.6502	0.013*

Table 2 (continued)

Atom	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso} [*] / <i>U</i> _{eq}
C9	0.87727(18)	0.4463(2)	0.6612(3)	0.0099(5)
H9A	0.9441	0.4223	0.6956	0.012*
C10	0.83949(18)	0.5010(2)	0.7848(3)	0.0086(5)
C11	0.87928(18)	0.4708(2)	0.9285(3)	0.0100(5)
H11A	0.9308	0.4171	0.9490	0.012*
C12	0.8441(2)	0.5186(2)	1.0420(3)	0.0128(5)
H12A	0.8712	0.4987	1.1402	0.015*
C13	0.76933(19)	0.5953(2)	1.0087(3)	0.0119(5)
C14	0.72730(19)	0.6266(2)	0.8678(3)	0.0122(6)
H14A	0.6749	0.6790	0.8481	0.015*
C15	0.76382(18)	0.5793(2)	0.7566(3)	0.0109(5)
H15A	0.7368	0.6007	0.6589	0.013*
C16	0.92191(19)	0.6252(2)	0.5241(3)	0.0099(5)
H2N3	0.929(2)	0.734(3)	0.385(4)	0.021(10)*
H1N3	0.852(2)	0.658(2)	0.329(3)	0.004(7)*

Source of material

3-(4-Bromophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1*H*-pyrazole-1-carbothioamide was synthesized from reaction of a mixture of (*E*)-1-(4-bromophenyl)-3-(4-fluorophenyl)prop-2-en-1-one, thiosemicarbazide and two mole equivalents of sodium hydroxide in ethanol under reflux for 3 h. The solid was filtered, dried and recrystallized from dimethylformamide to give colorless crystals of the title compound (Mp 270–271°C) [1, 2].

Experimental details

C-bound H atoms were placed in calculated positions (C—H 0.93 Å) and were included in the refinement in the riding model approximation, with *U*_{iso}(H) set to 1.2*U*_{eq}(C). The nitrogen-bound H atoms was located on a difference Fourier map and refined freely.

Discussion

*N*¹-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1*H*)pyrazoles are useful as MAO inhibitors against monoamine oxidases which were isolated and purified from the mitochondrial extracts of rat liver homogenates and human platelets [3]. Corresponding derivatives have antimicrobial and antidepressant activities

[4, 5]. In the title compound, C₁₆H₁₃BrFN₃S, the asymmetric unit contains only one independent molecule. The central pyrazolyl ring (N1/N2/C7–C9) makes a dihedral angles of 14.71(2)° and 80.41(3)° with the plane of the bromophenyl ring (C1–C6) and the plane of the fluorophenyl ring (C10–C15), respectively. The packing of the structure shows two weak hydrogen bonds between N3–H1N3···F1ⁱ and C15–H15A···Br1ⁱⁱ. (symmetry code: (i) *x*, *y*, *z*–1; (ii) *–x*+1, *y*+1/2, *–z*+1/2.

Acknowledgements: The authors extend their appreciation to the Deanship of Scientific Research and the Research Center, College of Pharmacy, King Saud University for their funding of this research.

References

- Khalil, O. M.; Refaat, H. M.: Synthesis and anti-inflammatory activity of some 3,5-diaryl-2-pyrazoline derivatives. *Oriental J. Chem.* **27** (2011) 1581–1590.
- Koç, G.Ş.; Tan, O. U.; Uçar, G.; Yıldırım, E.; Erol, K.; Palaska, E.: Synthesis and monoamine oxidase inhibitory activities of some 3-(4-fluorophenyl)-5-aryl-*N*-substituted-4,5-dihydro-(1*H*)-pyrazole-1-carbothioamide derivatives. *Drug Res.* **64** (2014) 591–598.
- Palaska, E.; Aydın, F.; Uçar, G.; Erol, D.: Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1*H*-pyrazole derivatives. *Arch. Pharm.* **341** (2008) 209–215.
- Abdel-Wahab, B. F.; Abdel-Latif, E.; Mohamed, H. A.; Awad, G. E. A.: Design and synthesis of new 4-pyrazolin-3-yl-1,2,3-triazoles and 1,2,3-triazol-4-yl-pyrazolin-1-ylthiazoles as potential antimicrobial agents. *Eur. J. Med. Chem.* **52** (2012) 263–268.
- Lv, P.-C.; Li, D.-D.; Li, Q.-S.; Lu, X.; Xiao, Z.-P.; Zhu, H.-L.: Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. *Bioorg. Med. Chem. Lett.* **21** (2011) 5374–5377.
- Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr.* **A64** (2008) 112–122.
- Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, WI, USA, 2009.